Enjoy complimentary customisation on priority with our Enterprise License!
The female sexual dysfunction treatment market size is estimated to grow at a CAGR of 34.28% between 2022 and 2027. The female sexual dysfunction treatment market is forecast to increase by USD 7,760.77 million. The growth of the market depends on several factors, including the increasing prevalence of chronic diseases, growing awareness of female sexual dysfunction, and approval and availability of drugs to treat hypoactive sexual desire disorder.
This market report extensively covers market segmentation by age group (above 40 years and below 40 years), product (non-hormonal therapy and hormonal therapy), and geography (North America, Europe, Asia, and Rest of World (ROW)). It also includes an in-depth analysis of drivers, trends, and challenges. Furthermore, the report includes historic market data from 2017 to 2021.
To learn more about this report, View Report Sample
The growing awareness of female sexual dysfunction is notably driving the market growth, although factors such as the adverse effects of drugs used in female sexual dysfunction treatment may impede the market growth. Our researchers analyzed the data with 2022 as the base year, along with the key drivers, trends, and challenges. A holistic analysis of drivers will help companies refine their marketing strategies to gain a competitive advantage.
Increased awareness of female sexual dysfunctions among women will drive the market's growth during the forecast period. The International Society for Sexual Medicine plays a leading role in ensuring that the latest evidence-based scientific developments in sexual medicine reach the entire target audience of both male and female sexual health practitioners and patients around the world. The organization focuses on investing in improved communications and marketing with the goal of providing more awareness, appreciation, and support for sexual medicine/health. Right to desire is a campaign for women with sexual dysfunctions. It is sponsored by Sprout Pharmaceuticals and aims to educate women regarding female sexual dysfunctions.
In addition, W2O Group, in collaboration with the American Sexual Health Association, launched an education program called Find My Spark. The program aims to encourage women to speak with their partners and health-care providers about any sexual difficulties they are facing. All such initiatives will contribute to the growth of the market during the forecast period.
Safety label changes for female sexual dysfunction therapy will accelerate market growth during the forecast period. Addyi was approved in August 2015 for the treatment of hypoactive sexual desire disorder in women. However, US FDA reviewed data that included several concerning cases of severe low blood pressure and death when flibanserin and alcohol were taken together. Therefore, in April 2019, US FDA issued a safety labelling change order to Sprout Pharmaceuticals, which needs the company to revise the safety information for Addyi. The recent labelling of Addyi includes a box stating that alcohol must be avoided in women treated with flibanserin.
Furthermore, US FDA instructed the company to take a risk evaluation and mitigation strategy for Addyi by certified healthcare professionals and pharmacies with the risk evaluation and mitigation strategy program for the product and by counselling patients about the risk of hypotension and syncope. In addition, US FDA wanted Sprout Pharmaceuticals to study further the interaction between flibanserin and alcohol after approval. Such initiatives will increase patient compliance, thereby accelerating the market's growth during the forecast period.
The adverse effects of drugs used in female sexual dysfunction treatment are the major challenge impeding the market growth. Sexual dysfunctions in women can be treated with hormonal therapy, which includes estrogen therapy and androgen therapy, as well as drugs, such as ospemifene (Osphena) and flibanserin (Addyi). However, these treatments are associated with adverse effects. The potential adverse effects of estrogen and androgen therapy include risks of breast and ovarian cancer, stroke, pulmonary thromboembolism, and vision loss caused by a blood clot in the eye. Osphena is an estrogen agonist which is prescribed for painful intercourse. The dose of Osphena is a 60 mg tablet, which needs to be taken once daily with food. The drug can cause cardiovascular disorders and malignant neoplasms.
According to clinical trials, incidence rates of thromboembolic and hemorrhagic stroke were 0.72 per 1,000 women and 1.45 per 1,000 women, respectively. Moreover, Osphena can cause allergic conditions, including hypersensitivity, angioedema, rash, rash erythematous, generalized rash, pruritus, and urticaria. Similarly, flibanserin can cause central nervous system depression with somnolence and sedation. It can also cause hypotension and syncope. Therefore, such adverse effects associated with the treatment of sexual dysfunctions in women can decrease patient compliance, thereby leading to a decline in the market's growth during the forecast period.
The market report includes the adoption lifecycle of the market, covering from the innovator’s stage to the laggard’s stage. It focuses on adoption rates in different regions based on penetration. Furthermore, the report also includes key purchase criteria and drivers of price sensitivity to help companies evaluate and develop their growth strategies.
Global Female Sexual Dysfunction Treatment Market Customer Landscape
Vendors are implementing various strategies, such as strategic alliances, partnerships, mergers and acquisitions, geographical expansion, and product/service launches, to enhance their presence in the market.
Pfizer - The company offers female sexual dysfunction treatment such as questionnaires and screeners. The company is engaged in the discovery, development, manufacturing, marketing, sales, and distribution of biopharmaceutical products worldwide.
The market report also includes detailed analyses of the competitive landscape of the market and information about 15 market vendors, including:
Qualitative and quantitative analysis of vendors has been conducted to help clients understand the wider business environment as well as the strengths and weaknesses of key market players. Data is qualitatively analyzed to categorize vendors as pure play, category-focused, industry-focused, and diversified; it is quantitatively analyzed to categorize vendors as dominant, leading, strong, tentative, and weak.
Based on age group, the market is segmented into above 40 years and below 40 years. The market share growth of the above 40 years segment will be significant during the forecast period. The above 40 years segment in the global female sexual dysfunction treatment market is expected to witness significant growth during the forecast period. This is due to the rising number of incidents of CVDs, diabetes, and cancer among the above 40 years age group. The prevalence of chronic diseases in the segment is expected to increase the patient pool and hence the segment growth during the forecast period.
Get a glance at the market contribution of various segments View PDF Sample
The above 40 years segment was valued at USD 422.63 million in 2017 and continued to grow until 2021. The prevalence of cardiovascular diseases (CVDs) was high in many countries like India. Approximately 4.77 million were diagnosed as positive, with 20.2% diabetes, 53.7% hypertension, 77% overweight/obesity, and 92% central obesity in 2020. Similarly, in the UK, around 7600 women above 40 years were diagnosed with breast cancer in 2020. Such factors are anticipated to drive the demand for female sexual dysfunction treatment in the above 40 years segment, which is expected to fuel the growth of the market during the forecast period.
For more insights on the market share of various regions View PDF Sample now!
North America is projected to account for 61% of the global market share growth by 2027. Technavio’s analysts have elaborately explained the regional trends and drivers that shape the market during the forecast period.
The female sexual dysfunction treatment market in North America is led by the US. According to the data published by the CDC in 2020, nearly 9.5% of women in the US were diagnosed with diabetes during 2017-2018. The prevalence of breast cancer in the US was found to be 128.3 per 100,000 women. Therefore, the rising prevalence of chronic diseases will increase the risk and incidence of sexual dysfunction in women, which will drive market growth in the region during the forecast period. In addition, according to the data provided by the Blue Cross Blue Shield Association, a federation of 36 separate US health insurance companies, nearly 43% of American women were estimated to experience female sexual dysfunction to some degree every year across the US. An expected rise in the incidence of sexual dysfunction among women is expected to boost the demand for treatment, which in turn, is also expected to increase the growth opportunities in the market in North America during the forecast period.
In 2020, the outbreak of COVID-19 had a negative impact on the regional market. However, in 2021, due to the availability of vaccines, the number of COVID-19 cases declined in the region. Owing to the ease of COVID-19-related restrictions and with access to hospitals and clinics being restored, the demand for female sexual dysfunction treatment drugs rebounded in 2021. Thus, owing to these factors, the regional market is expected to witness growth during the forecast period.
The female sexual dysfunction treatment market report forecasts market growth by revenue at global, regional & country levels and provides an analysis of the latest trends and growth opportunities from 2017 to 2027.
Female Sexual Dysfunction Treatment Market Scope |
|
Report Coverage |
Details |
Page number |
156 |
Base year |
2022 |
Historic period |
2017-2021 |
Forecast period |
2023-2027 |
Growth momentum & CAGR |
Accelerate at a CAGR of 34.28% |
Market growth 2023-2027 |
USD 7,760.77 million |
Market structure |
Fragmented |
YoY growth (%) |
32.7 |
Regional analysis |
North America, Europe, Asia, and Rest of World (ROW) |
Performing market contribution |
North America at 61% |
Key countries |
US, Canada, Germany, UK, and France |
Competitive landscape |
Leading Vendors, Market Positioning of Vendors, Competitive Strategies, and Industry Risks |
Key companies profiled |
Assos Ilac, Cipla Ltd., Dare Bioscience Inc., Dr Reddys Laboratories Ltd., Duchesnay Inc., Endo International Plc, Freya Pharma Solutions B.V., Lupin Ltd., Mithra Pharmaceuticals SA, Novo Nordisk AS, Palatin Technologies Inc., Pfizer Inc., Pharmbio Korea Inc., Sprout Pharmaceuticals Inc., Strategic Science and Technologies LLC, Teva Pharmaceutical Industries Ltd., and Viatris Inc. |
Market dynamics |
Parent market analysis, Market growth inducers and obstacles, Fast-growing and slow-growing segment analysis, COVID-19 impact and recovery analysis and future consumer dynamics, and market condition analysis for the forecast period. |
Customization purview |
If our report has not included the data that you are looking for, you can reach out to our analysts and get segments customized. |
Get access to Report Sample PDF !
We can help! Our analysts can customize this market research report to meet your requirements. Get in touch
Get lifetime access to our
Technavio Insights
Cookie Policy
The Site uses cookies to record users' preferences in relation to the functionality of accessibility. We, our Affiliates, and our Vendors may store and access cookies on a device, and process personal data including unique identifiers sent by a device, to personalise content, tailor, and report on advertising and to analyse our traffic. By clicking “I’m fine with this”, you are allowing the use of these cookies. Please refer to the help guide of your browser for further information on cookies, including how to disable them. Review our Privacy & Cookie Notice.